Prefilled syringes reduce rate of endophthalmitis after intravitreal injection

Use of prefilled syringes (PFS) of anti–vascular endothelial growth factor (VEGF) therapies for intravitreal injections significantly reduces the rate of endophthalmitis compared to the use of a traditional glass vial, according to a poster presented at AAO 2022.

In this retrospective study, data from 294,862 injections were analyzed. Overall, there were 97 cases of endophthalmitis identified (0.033%), with 51 of them occurring in the vial group of aflibercept and ranibizumab (0.052%) and 24 occurring in the PFS group (0.018%).

The authors concluded that were PFS were associated with a decreased risk of endophthalmitis (OR 0.34; 95% CI, 0.21-0.56; P < 0.001).

Reference
Louis AM, et al. Impact of Prefilled Syringes and Masking on Post–Intravitreal Injection Endophthalmitis.Poster presented at: AAO 2022.